This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Overcoming Clinical Challenges in Alzheimer's Disease: Implementing Novel Diagnostic Methods and Therapies

Overcoming Clinical Challenges in Alzheimer's Disease: Implementing Novel Diagnostic Methods and Therapies

Format

Roundtable

Time to Complete

1.25 hours

Released

October 22, 2018

Expires

October 22, 2019
Add to Queue


Maximum Credits

1.25 / AMA PRA Category 1 CreditTM
1.10 / CE for Nurses (0.50 pharmacotherapy credit)

Joint Providers

Jointly provided by Postgraduate Institute for Medicine (PIM) and ASiM.

Commercial Supporter

Supported by an educational grant from Biogen.

Program Description

New developments in the diagnosis of Alzheimer’s Disease (AD), as well as the recent wave of emerging treatments, have left many clinicians unsure about the next steps in diagnosing and treating patients with this debilitating and deadly disease. Recognizing dementia and AD in its early stages is crucial, not only to achieve the best outcomes with available therapies, but also to advance the development of disease modifying therapies (DMTs). Unfortunately, the clinical challenges associated with AD recognition can lead to delayed diagnosis and subsequent missed opportunities for early intervention. This interactive video activity features a panel discussion among 3 AD experts covering recent diagnostic advances in AD – particularly prodromal/early AD – and their potential impacts on improving health outcomes. Expert clinical faculty also discuss highlights of the latest study results of AD DMTs presented at the 33rd International Conference of Alzheimer’s Disease International (July 28, 2018) in Chicago, Illinois.

Intended Audience

This educational activity will be designed for neurologists and primary care providers (physicians, physician assistants, and nurse practitioners), as well as other healthcare providers who care for patients with AD.

Educational Objectives

After completing this activity, the participant should be better able to:

  • REVIEW potential benefits, risks, and challenges with diagnosing AD early in the disease course.
  • IMPLEMENT strategies to recognize and diagnose dementia and AD.
  • DEVELOP a therapeutic regimen for the management of patients from early to late-stage AD.
  • EVALUATE the potential benefits, risks, and clinical implications of late-stage investigational therapies for AD.

Conflict Of Interest Disclosure Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Jeffrey L. Cummings, MD, ScD (Chair)
Director, Center for Neurodegeneration and Translational Neuroscience
Director strongeritus, Cleveland Clinic Lou Ruvo Center for Brain Health
Professor, Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Dr. Cummings discloses the following:
Salary: Cleveland Clinic.
Royalties: Neuropsychiatric Inventory (NPI).
Consultant: ACADIA Pharmaceuticals Inc, Accera Inc, Actinogen Medical, Adamas Pharmaceuticals Inc, Alkahest Inc, Allergan Inc, Alzheon Inc, Avanir Pharmaceuticals Inc, Axovant Sciences Inc, Axsome Therapeutics Inc, Bioasis Technologies Inc, Biogen, Bracket assessment companies, Eisai Co Ltd, F Hoffmann-La Roche Ltd, Genentech Inc, Grifols, Kyowa, Lilly & Co Inc, Lundbeck LLC, MedAvante-ProPhase Inc, Merck & Co Inc, NeuroCog, Nutricia, Otsuka, QR Pharma Inc, Resverlogix Corp, Samus Therapeutics Inc, Servier, Suven Life Sciences Limited, Takeda Pharmaceutical Company Limited, Toyoma, and United Neuroscience companies.
Stock: Adamas Pharmaceuticals Inc, Alzheon Inc, Bioasis Technologies Inc, EIP Pharma, MedAvante-ProPhase Inc, NeuroTrax Corporation, Prana Biotechnology Limited, QR Pharma Inc, and Sonexa Therapeutics.
Grants/Research Support: Avid Radiopharmaceuticals and Teva.

Liana Apostolova, MD, MSc, FAAN
Barbara and Peer Baekgaard Professor in AD Research
Professor in Neurology, Radiology, Medical and Molecular Genetics
Indiana University School of Medicine
Indiana Alzheimer’s Disease Center
Indianapolis, Indiana

Dr. Apostolova discloses the following:
Consultant: Biogen, Bracket, MedAvante-ProPhase Inc, and Eisai Co Ltd.
Grants/Research Support: Novartis AG.

James Galvin, MD, MPH
Associate Dean for Clinical Research and Professor of Integrated Medical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida

Dr. Galvin discloses the following:
Consultant: Biogen, Bracket, MedAvante-ProPhase Inc, and Eisai Co Ltd.
Grants/Research Support: Novartis.

PLANNERS AND MANAGERS DISCLOSURES

The PIM planners and managers have nothing to disclose.
The ASiM CE LLC planners and managers have nothing to disclose.

Credit

1.25

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.10

Type

CE for Nurses

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ASiM CE LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.10 contact hours. Designated for 0.50 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

There are no fees for participating and receiving CME or CNE credit for this activity. During the period October 22, 2018 through October 22, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

To obtain credit a score of 75% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue